Tempus AI, Inc. (TEM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Should You Buy, Hold or Sell TEM Stock Post Q3 Earnings Release?
Tempus AI posts first positive adjusted EBITDA and 84.7% revenue surge, signaling new growth momentum amid premium valuation.
Tempus AI: Volatility Equates to Opportunity in AI Leader
Tempus AI's NASDAQ: TEM stock price pulled back in early November following its Q3 release, aligning with broader market action and opening a buying opportunity for investors. The primary concern is the valuation, which is admittedly high relative to its current-year outlook.
TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours
Tempus AI reports a narrower-than-expected Q3 loss and stronger revenues, raises full-year outlook, but shares decline following the results.
Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Tempus (TEM) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tempus AI, Inc. (TEM) Q3 2025 Earnings Call Transcript
Tempus AI, Inc. ( TEM ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eric Lefkofsky - Co-Founder, CEO, President & Chairman James Rogers - Chief Financial Officer Conference Call Participants Ryan MacDonald - Needham & Company, LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Colleen Babington - Wolfe Research, LLC Parth Talsania - Equisights Ricki Levitus - Guggenheim Securities, LLC, Research Division David Westenberg - Piper Sandler & Co., Research Division Mark Schappel - Loop Capital Markets LLC, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Tempus AI Third Quarter 2025 Financial Results Conference Call.
This AI Health Stock is Up Over 150% This Year—and It's Not Slowing Down
Tempus AI (NASDAQ:TEM) isn't an AI stock that immediately comes to mind when one thinks of machine-learning-driven technological innovators with disruptive potential.
TEM vs. EXAS: Which Genomics Player Offers Greater Upside?
Tempus AI's soaring genomics revenues and Exact Sciences' diagnostic breakthroughs spotlight two distinct routes to precision oncology growth.
Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?
TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.
Tempus AI Hits $100—Are Shares Due for a Pullback?
Tempus AI NASDAQ: TEM has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a whopping 155% on Monday, Oct. 13.
TEM Expands Partnership With Northwestern Medicine Amid AI Boom
Tempus AI deepens its collaboration with Northwestern Medicine, embedding its AI co-pilot David directly into the health system's EHR to boost clinical efficiency.
Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?
Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.
